Decreased breast cancer-specific mortality risk in patients with a history of thyroid cancer

Autoři: Weiwei Cheng aff001;  Xiaopei Shen aff001;  Mingzhao Xing aff001
Působiště autorů: Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America aff001
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: 10.1371/journal.pone.0221093


Previous studies have documented an intrinsic association between breast cancer (BC) and thyroid cancer (TC), but the clinical relevance of this relationship is not well defined. In the present study, we specifically investigated the impact of a history of TC on clinical outcomes of BC. We performed a population-based comparative analysis of tumor behaviors and BC-specific mortalities in 427,893 female patients with BC in the USA Surveillance, Epidemiology and End Results 9 database (1973–2013). In this cohort of subjects, 2,569 patients also had a history of differentiated TC (BC/TC), including BC diagnosed before TC (BC-1st) and BC diagnosed after TC (TC-1st), with the median follow-up time of 81 (IQR, 33–160) months. We found that, compared with matched BC-only patients, less aggressive BC tumor behaviors occurred in BC/TC patients, as exemplified by a distant metastasis rate of 7.0% in the former versus 3.3% in the latter (P<0.001). In BC/TC, BC-1st, and TC-1st patients versus their matched BC-only patients, BC-specific mortalities were 11.3% versus 21.0%, 9.9% versus 26.4%, and 12.4% versus 16.9%. These corresponded to hazard ratios (HR) (95% CI) of 0.47 (0.42–0.53), 0.31 (0.26–0.37), and 0.72 (0.61–0.84), respectively (all P<0.001), being lowest in BC-1st patients <50 years old [HR = 0.22 (0.16–0.31)], which remained significant after adjustment for clinicopathological and socioeconomic factors. Estrogen/progesterone receptor expression in BC tumors was significantly higher in patients with BC/TC than matched BC-only patients, providing evidence that BC in the former was biologically unique. Thus, a history of TC, particularly in younger BC-1st patients, may identify BC as a unique disease entity characterized by a decreased disease-specific mortality risk. The results have potentially important clinical and biological implications for BC in this special patient population and encourage further studies to confirm.

Klíčová slova:

Breast cancer – Cancer detection and diagnosis – Death rates – Insurance – Metastasis – Patients – Prognosis – Thyroid carcinomas


1. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66: 31–42. doi: 10.3322/caac.21320 26513636

2. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al. SEER Cancer Statistics Review, 1975–2014, National Cancer Institute. Bethesda, MD,, based on November 2016 SEER data submission, posted to the SEER web site, April 2017.

3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66: 7–30. doi: 10.3322/caac.21332 26742998

4. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26: 1–133. doi: 10.1089/thy.2015.0020 26462967

5. An JH, Hwangbo Y, Ahn HY, Keam B, Lee KE, Han W, et al. A possible association between thyroid cancer and breast cancer. Thyroid.2015;25: 1330–1338. doi: 10.1089/thy.2014.0561 26442580

6. Consorti F, Di Tanna G, Milazzo F, Antonaci A. Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer. World J Surg Oncol. 2011;9: 88. doi: 10.1186/1477-7819-9-88 21835042

7. Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I, et al. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid. 2017;17: 1277–1288.

8. Kuo JH, Chabot JA, Lee JA. Breast cancer in thyroid cancer survivors: An analysis of the Surveillance, Epidemiology, and End Results-9 database. Surgery. 2016;159: 23–29. doi: 10.1016/j.surg.2015.10.009 26522696

9. Nielsen SM, White MG, Hong S, Aschebrook-Kilfoy B, Kaplan EL, Angelos P, et al. The breast-thyroid cancer link: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2016;25: 231–238. doi: 10.1158/1055-9965.EPI-15-0833 26908594

10. Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014; 120: 1290–1314. doi: 10.1002/cncr.28509 24343171

11. Richardson LC, Henley SJ, Miller JW, Massetti G, Thomas CC. Patterns and Trends in Age-Specific Black-White Differences in Breast Cancer Incidence and Mortality—United States, 1999–2014. MMWR Morb Mortal Wkly Rep. 2016;65: 1093–1098. doi: 10.15585/mmwr.mm6540a1 27736827

12. Welch HG, Prorok PC, O'Malley AJ, Kramer BS. Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness. N Engl J Med 2016;375: 1438–1447. doi: 10.1056/NEJMoa1600249 27732805

13. Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 2001;12: 703–711. 11562110

14. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Invest Dermatol.2009;129: 1666–1674. doi: 10.1038/jid.2008.423 19131946

15. NCCN Guidelines for invasive breast cancer (Version 3.2017).

16. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genetics.1997;16: 64–67. doi: 10.1038/ng0597-64 9140396

17. Ngeow J, Stanuch K, Mester JL, Barnholtz-Sloan JS, Eng C. Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations. J Clin Oncol.2014; 32: 1818–1824. doi: 10.1200/JCO.2013.53.6656 24778394

18. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst.1994; 86: 1600–1608. doi: 10.1093/jnci/86.21.1600 7932824

19. Patani N, Martin L-A, Dowsett M. Biomarkers for the clinical management of breast cancer: international perspective. Int J Cancer.2013;133: 1–13. doi: 10.1002/ijc.27997 23280579

20. van de Vijver MJ. Molecular tests as prognostic factors in breast cancer. Virchows Arch. 2014; 464:283–291. doi: 10.1007/s00428-014-1539-0 24487789

Článek vyšel v časopise


2019 Číslo 10